Potent Inhibitors

During the drug discovery program for gout, we sought to optimize the effects on uric acid and eliminate possible side effects. We also altered the target profile for enzyme inhibition by ensuring immediate onset of action against both targets. Our final drug candidates were required to allow once-per-day oral dosing in patients. Each of these objectives has been achieved, and Relburn is currently proceeding with late-stage preclinical testing to enable initiation of clinical trials.